HPN328, a Trispecific T Cell-activating Protein Construct Targeting DLL3-Expressing Solid Tumors.
Molloy ME, Aaron WH, Barath M, Bush MC, Callihan EC, Carlin K, Cremin M, Evans T, Gamez Guerrero M, Hemmati G, Hundal AS, Lao L, Laurie P, Lemon BD, Lin SJ, O'Rear J, Patnaik P, Sotelo Rocha S, Santiago L, Strobel KL, Valenzuela LB, Wu CH, Yu S, Yu TZ, Anand BS, Law CL, Sun LL, Wesche H, Austin RJ.
Molloy ME, et al. Among authors: wu ch.
Mol Cancer Ther. 2024 Apr 27. doi: 10.1158/1535-7163.MCT-23-0524. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38670552
In an immunocompetent mouse model expressing a human CD3epsilon epitope, mice previously treated with HPN328 withstood tumor rechallenge, demonstrating long-term anti-tumor immunity. When repeat doses were administered to cynomolgus monkeys, HPN328 was well tolerated up to …
In an immunocompetent mouse model expressing a human CD3epsilon epitope, mice previously treated with HPN328 withstood tumor rechallenge, de …